Phathom Pharmaceuticals (PHAT) Competitors $11.91 +0.96 (+8.77%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$11.92 +0.02 (+0.13%) As of 08/22/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. AMRX, RARE, KYMR, IMVT, HCM, XENE, ALVO, CRNX, GMTX, and CPRXShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include AMNEAL PHARMACEUTICALS (AMRX), Ultragenyx Pharmaceutical (RARE), Kymera Therapeutics (KYMR), Immunovant (IMVT), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), Gemini Therapeutics (GMTX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors AMNEAL PHARMACEUTICALS Ultragenyx Pharmaceutical Kymera Therapeutics Immunovant HUTCHMED Xenon Pharmaceuticals Alvotech Crinetics Pharmaceuticals Gemini Therapeutics Catalyst Pharmaceuticals Phathom Pharmaceuticals (NASDAQ:PHAT) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. Which has higher earnings & valuation, PHAT or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$114.04M7.41-$334.33M-$4.73-2.52Amneal Pharmaceuticals$2.79B1.08-$116.89M$0.01959.00 Which has more volatility & risk, PHAT or AMRX? Phathom Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Do analysts rate PHAT or AMRX? Phathom Pharmaceuticals currently has a consensus price target of $17.50, suggesting a potential upside of 46.94%. Amneal Pharmaceuticals has a consensus price target of $11.60, suggesting a potential upside of 20.96%. Given Phathom Pharmaceuticals' higher possible upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of PHAT or AMRX? 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is PHAT or AMRX more profitable? Amneal Pharmaceuticals has a net margin of 0.12% compared to Phathom Pharmaceuticals' net margin of -289.51%. Phathom Pharmaceuticals' return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-289.51% N/A -90.40% Amneal Pharmaceuticals 0.12%-189.49%6.17% Does the media refer more to PHAT or AMRX? In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 2 mentions for Phathom Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.11 beat Phathom Pharmaceuticals' score of 0.38 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmneal Pharmaceuticals beats Phathom Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$776.84M$3.11B$5.76B$9.61BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-2.5221.1431.2226.05Price / Sales7.41346.56435.14103.68Price / CashN/A43.1937.7358.48Price / Book-2.088.129.536.61Net Income-$334.33M-$54.72M$3.26B$265.65M7 Day Performance16.31%2.62%2.12%2.03%1 Month Performance38.97%2.68%2.81%-0.30%1 Year Performance-13.95%10.93%30.62%19.06% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals2.6057 of 5 stars$11.91+8.8%$17.50+46.9%-7.0%$776.84M$114.04M-2.52110AMRXAMNEAL PHARMACEUTICALS3.3097 of 5 stars$8.84+3.5%$11.60+31.2%+19.1%$2.68B$2.79B884.888,100News CoveragePositive NewsInsider TradeRAREUltragenyx Pharmaceutical4.7212 of 5 stars$27.39-0.5%$81.50+197.6%-47.2%$2.65B$560.23M-4.951,294News CoverageKYMRKymera Therapeutics2.7203 of 5 stars$37.68-7.2%$59.11+56.9%-3.8%$2.65B$47.07M-12.15170High Trading VolumeIMVTImmunovant3.0012 of 5 stars$14.76-4.5%$35.33+139.4%-51.5%$2.64BN/A-5.39120HCMHUTCHMED2.6645 of 5 stars$15.48+3.2%$28.00+80.9%-10.0%$2.62B$630.20M0.001,811XENEXenon Pharmaceuticals2.0374 of 5 stars$34.11+2.0%$54.33+59.3%+0.5%$2.57B$9.43M-10.56210News CoverageOptions VolumeALVOAlvotech2.3799 of 5 stars$8.52+0.7%$14.00+64.3%-29.4%$2.55B$491.98M23.031,032News CoverageShort Interest ↓Gap UpCRNXCrinetics Pharmaceuticals3.6711 of 5 stars$27.38+2.0%$68.86+151.5%-41.9%$2.53B$1.04M-6.66210News CoverageInsider TradeGMTXGemini TherapeuticsN/A$58.03+1.7%N/A+22.6%$2.51BN/A-58.0330CPRXCatalyst Pharmaceuticals4.8891 of 5 stars$19.68-0.9%$33.20+68.7%+1.6%$2.43B$491.73M11.9380Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies AMNEAL PHARMACEUTICALS Alternatives Ultragenyx Pharmaceutical Alternatives Kymera Therapeutics Alternatives Immunovant Alternatives HUTCHMED Alternatives Xenon Pharmaceuticals Alternatives Alvotech Alternatives Crinetics Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access